PTI

Proteostasis
NASDAQ

实时行情|Nasdaq Last Sale

1.130
+0.090
+8.65%
盘后: 1.130 0 0.00% 19:41 04/03 EDT
开盘
1.050
昨收
1.040
最高
1.140
最低
1.040
成交量
44.14万
成交额
--
52周最高
4.720
52周最低
0.6100
市值
5,892.69万
市盈率(TTM)
-0.9771
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PTI价格均价为5.50,最高价位8.00,最低价为3.000。

EPS

PTI 新闻

更多
  • RDS.A, NRZ among premarket gainers
  • Seeking Alpha - Article · 03/19 13:20
  • Proteostasis Therapeutics EPS beats by $0.06
  • seekingalpha · 03/11 01:41
  • Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
  • PR Newswire · 03/10 21:36
  • Proteostasis Says Sees Dosing In CHOICES Trial Expected To Begin H2'20, Sees Prelim. Clinical Data Early '21
  • Benzinga · 03/10 20:42

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

PTI 简况

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of novel therapeutics to treat cystic fibrosis (CF), and other diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. The Company focuses on identifying therapies that restore protein function. The Company’s CF focused pipeline consists of novel CFTR modulators including correctors, potentiators and amplifiers. The Company’s clinical developments include PTI-801, a third generation CFTR corrector, PTI-808, a CFTR potentiator, and PTI-428, a CFTR amplifier.
展开

微牛提供Proteostasis Therapeutics Inc(NASDAQ-PTI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PTI股票新闻,以帮助您做出投资决策。